Compare SND & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SND | CGEN |
|---|---|---|
| Founded | 2011 | 1993 |
| Country | United States | Israel |
| Employees | 318 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.6M | 191.1M |
| IPO Year | 2016 | 2001 |
| Metric | SND | CGEN |
|---|---|---|
| Price | $5.19 | $2.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 243.0K | ★ 306.7K |
| Earning Date | 05-05-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $330,153,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $34.67 | ★ N/A |
| Revenue Growth | ★ 6.03 | N/A |
| 52 Week Low | $1.88 | $1.30 |
| 52 Week High | $5.92 | $3.24 |
| Indicator | SND | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 60.50 | 55.21 |
| Support Level | $4.55 | $2.54 |
| Resistance Level | $5.29 | $2.99 |
| Average True Range (ATR) | 0.22 | 0.13 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 77.17 | 50.39 |
Smart Sand Inc. is a fully integrated frac sand company providing mine-to-well site proppant supply and logistics. It produces Northern White frac sand for enhanced hydrocarbon recovery in oil and gas wells. The company offers products like Smart System, SmartBelt, SmartDepot Silo, and SmartPath Loader. It is expanding into industrial markets, including glass, ceramics, and renewable energy, while its main revenue comes from sand sales and logistics. The company has two reportable segments, Sand and SmartSystems. It derives maximum revenue from Sand segment, which includes both frac sand sales and IPS sales. Geographically, the company derives maximum revenue from United States, followed by Canada.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.